文献速递神经肿瘤脊柱脊髓外科

成人H3 K27变异型弥漫性中线胶质瘤的早期远处进展

Early distant progression in adult Histone-3 K27-altered diffuse midline gliomas.
PubMed 文献 · J Neurooncol · 2026-01-13

该回顾性多中心队列研究纳入52例成人H3 K27变异型弥漫性中线胶质瘤患者,分析远处进展的临床与分子预测因素。结果显示10例(19%)发生远处进展,其中70%原发位于脊髓(p < 0.001),且近80%脊髓DMG患者出现远处进展。远处进展与更差的无进展生存期相关(4.5 vs. 13个月;p = 0.037),但未发现与远处进展显著相关的遗传或甲基化特征。

要点

  • 成人DMG远处进展发生率为19%,脊髓原发者风险显著更高。
  • 脊髓DMG患者中近80%出现远处进展,应常规行全脑全脊髓MRI。
  • 远处进展与更短的无进展生存期相关(4.5 vs. 13个月)。

核心结论

  • 脊髓位置的成人DMG患者早期远处进展风险高,推荐常规行全脑全脊髓MRI。
  • 远处进展与更差的无进展生存期相关,但无分子标志可预测其发生。

研究设计与样本

  • 回顾性多中心队列研究,纳入52例成人H3 K27变异型弥漫性中线胶质瘤患者。
  • 采用基因panel测序和全基因组DNA甲基化芯片分析临床与分子预测因素。

主要发现

  • 52例中10例(19%)发生远处进展,包括软脑膜播散。
  • 10例远处进展者中7例(70%)原发位于脊髓(p < 0.001),脊髓DMG患者中近80%出现远处进展。
  • 远处进展与更差的无进展生存期相关(4.5 vs. 13个月;p = 0.037)。
  • 未发现与远处进展显著相关的遗传或甲基化特征。

关键数值与推荐

  • 远处进展定义为包括软脑膜播散在内的远处转移。
  • 脊髓原发位置与远处进展显著相关(p < 0.001)。
  • 远处进展组中位无进展生存期为4.5个月,无远处进展组为13个月(p = 0.037)。

临床怎么用

  • 成人DMG患者,尤其是脊髓原发者,应常规行全脑全脊髓MRI以监测远处进展。
  • 脊髓DMG患者需警惕早期远处播散,密切随访。

局限性

  • 回顾性研究设计,样本量较小(52例)。
  • 未发现分子预测标志,可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: H3 K27-altered diffuse midline glioma (DMG) is a molecularly defined, highly aggressive tumor entity since the 2016 revision of the World Health Organization (WHO) classification of tumors of the central nervous system (CNS). It has been most extensively characterized in children and adolescents and continues to pose significant challenges to treating physicians due to its growth along the midline structures of the brain and its ability to progress distantly leading to poor prognosis. Clinical and molecular determinants of distant progression and its impact on patient survival particularly in adults have not been thoroughly characterized. METHODS: This retrospective multicenter cohort study of 52 adult patients with DMG was analyzed for clinical and molecular predictors of distant tumor progression using gene panel sequencing and genome-wide DNA methylation arrays. RESULTS: Distant progression including leptomeningeal disease occurred in 10 out of 52 adult patients (19%), seven of which had a primary spinal tumor location (70%, p < 0.001) and almost 80% of patients with spinal DMG experienced distant progression. Across the entire cohort, distant progression was associated with worse progression free survival (PFS) (4.5 vs. 13 months; p = 0.037). However, we could not identify a genetic or methylation-based signature that was significantly correlated with the occurrence of distant progression. CONCLUSIONS: Adult DMGs with spinal location are at a high risk of early distant progression. As there were no molecular determinants of distant progression from differential methylation, copy number alterations (CNA) or panel sequencing, adult patients with DMG should undergo routine craniospinal MRI, particularly in spinal tumor location. • Distant progression occurs in one fifth of adult DMG patients, predominantly in tumors with spinal location. • Distant progression is associated with shorter progression-free survival and spinal tumor location. • There are no molecular signatures based on methylation, CNAs or panel sequencing that are associated with the risk of distant progression.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Grassl N, Suwala AK, Kessler T, et al. Early distant progression in adult Histone-3 K27-altered diffuse midline gliomas. J Neurooncol. 2026. PMID: 41528563. doi:10.1007/s11060-025-05238-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。